THE ANTILEUKEMIC ALKALOID FAGARONINE IS AN INHIBITOR OF DNA TOPOISOMERASE-I AND TOPOISOMERASE-II

被引:123
作者
LARSEN, AK
GRONDARD, L
COUPRIE, J
DESOIZE, B
COMOE, L
JARDILLIER, JC
RIOU, JF
机构
[1] RHONE POULENC RORER SA,CTR RECH VITRY ALFORTVILLE,F-94403 VITRY,FRANCE
[2] FAC PHARM REIMS,F-51100 REIMS,FRANCE
[3] FAC PHARM ABIDJAN,ABIDJAN 01,COTE IVOIRE
[4] INST JEAN GODINOT,GIBSA,F-51100 REIMS,FRANCE
关键词
D O I
10.1016/0006-2952(93)90105-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The antileukemic alkaloid, fagaronine, is a potent differentiation inducer of various hematopoietic cell lines. We show here that fagaronine is a DNA base-pair intercalator with a K(app) of 2.1 x 10(5) M-1 for calf thymus DNA. Fagaronine inhibits the catalytic activity of purified calf thymus topoisomerase I as shown by relaxation of supercoiled plasmid DNA followed by electrophoresis in neutral as well as in chloroquine-containing gels. The catalytic activity of topoisomerase I is inhibited at concentrations above 30 muM. Fagaronine also inhibits the catalytic activity of purified calf thymus topoisomerase II at concentrations above 25 muM as shown by decatenation of kinetoplast DNA. Fagaronine stabilizes the covalent DNA-enzyme reaction intermediate (the cleavable complex) between topoisomerase I and linear pBR322 DNA at concentrations up to 1 muM. Further increase of the fagaronine concentration leads to a progressive decrease in the cleavable complex formation, which is totally inhibited at 100 muM. In contrast, up to 1 muM fagaronine has no effect on cleavable complex formation between purified calf thymus topoisomerase II and linear pBR322 DNA, whereas cleavable complex formation is inhibited at higher concentrations. Exposure to fagaronine results in an increase in DNA-protein complex formation in intact P388 murine leukemia cells. P388CPT5 cells, which have an altered topoisomerase I activity, are 4-fold resistant to the growth inhibitory effects of fagaronine compared to the parental cell line. Similarly, DC-3F/9-OH-E Chinese hamster fibrosarcoma cells, which have an altered topoisomerase II activity, are about 5-fold resistant to the growth inhibitory effects of fagaronine. We conclude that fagaronine is an inhibitor of both DNA topoisomerase I and II and propose that this might play a role in the cytotoxic activity.
引用
收藏
页码:1403 / 1412
页数:10
相关论文
共 47 条
[1]  
ALLER P, 1992, CANCER RES, V52, P1245
[2]  
BAEZ A, 1990, MOL PHARMACOL, V37, P377
[3]  
BAGULEY BC, 1991, ANTI-CANCER DRUG DES, V6, P1
[4]   SURAMIN IS AN INHIBITOR OF DNA TOPOISOMERASE-II INVITRO AND IN CHINESE-HAMSTER FIBROSARCOMA CELLS [J].
BOJANOWSKI, K ;
LELIEVRE, S ;
MARKOVITS, J ;
COUPRIE, J ;
JACQUEMINSABLON, A ;
LARSEN, AK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (07) :3025-3029
[5]   REDUCED DNA TOPOISOMERASE-II ACTIVITY AND DRUG-STIMULATED DNA CLEAVAGE IN 9-HYDROXYELLIPTICINE RESISTANT CELLS [J].
CHARCOSSET, JY ;
SAUCIER, JM ;
JACQUEMINSABLON, A .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (11) :2145-2149
[6]   INDUCTION OF DIFFERENTIATION OF HUMAN AND MOUSE MYELOID-LEUKEMIA CELLS BY CAMPTOTHECIN [J].
CHOU, S ;
KANEKO, M ;
NAKAYA, K ;
NAKAMURA, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 166 (01) :160-167
[7]   THE ANTILEUKEMIC ALKALOID FAGARONINE AND THE HUMAN K-562 LEUKEMIC-CELLS - EFFECTS ON GROWTH AND INDUCTION OF ERYTHROID-DIFFERENTIATION [J].
COMOE, L ;
JEANNESSON, P ;
TRENTESAUX, C ;
DESOIZE, B ;
JARDILLIER, JC .
LEUKEMIA RESEARCH, 1987, 11 (05) :445-451
[8]   EFFECT OF FAGARONINE ON CELL-CYCLE PROGRESSION OF HUMAN ERYTHROLEUKEMIA K562 CELLS [J].
COMOE, L ;
CARPENTIER, Y ;
DESOIZE, B ;
JARDILLIER, JC .
LEUKEMIA RESEARCH, 1988, 12 (08) :667-672
[9]  
CONSTANTINOU A, 1989, CANCER RES, V49, P1110
[10]  
CONSTANTINOU A, 1990, CANCER RES, V50, P2618